Current goals of COPD management include minimizing exposure to risk factors, such as tobacco smoke, and interventions to improve lung function, exercise tolerance, and quality of life (QoL), while reducing complications, exacerbations, and mortality. This can be achieved using both pharmacologic and nonpharmacologic interventions.1 As with all pharmacologic therapies, the safety of COPD medications is influenced by factors relating either directly to the patient (age, comorbidities, adherence to instructions) or to the particular medication being used (pharmacologic properties, dose, duration, delivery route, and bioavailability).2,3 Although current guidelines focus primarily on the efficacy of these medications,1,4 safety should also be addressed in the ongoing management of COPD to ensure that the benefits of medications outweigh the risks of possible side effects. Important evidence exists from clinical trials conducted in support of the regulatory review and approval process, which establishes the efficacy and tolerability profile of pharmacologic treatments for COPD, and these data are reflected in product labeling. Further research conducted after approval provides additional data about the efficacy and safety of these medications, with longer follow-up and more inclusive patient populations than feasible in clinical trials conducted before approval. It is, therefore, important that clinicians understand and consider new postapproval data as they become available.